MedTech Industry Pulse: August 2026
Avania’s monthly briefing on the trends shaping MedTech regulatory strategy, funding, and market access, part of our MedTech insights and resources library. Here’s what mattered in August 2026.
Prefer a PDF to save or share internally? Download the full August 2026 report (PDF)
August 2026 at a Glance
- Industry-funded interventional clinical trial starts fell from 79 in July to 69 in August, continuing a decline from April’s high of 100.
- M&A activity was heavy: seven announced deals spanning cardiovascular, diagnostics, imaging, and connected-device categories, plus a strategic investment from Medtronic in Pi-Cardia with an option to purchase.
- Regulators in the United States and EU staked out early positions on AI oversight for medical devices, while CMS proposed a faster device coverage pathway alongside a new payment line for software.
- The FDA approved 3 PMAs, 5 De Novo devices, and 1 Humanitarian Device Exemption in August.
August 2026 Funding Successes
| Company | Country | Stage | Amount | Focus |
|---|---|---|---|---|
| Pi-Cardia | Israel | Strategic investment | up to $80M | Medtronic becomes commercial distributor with option to purchase Pi-Cardia |
| Happy Health | USA | Venture financing | $75M | Sleep diagnostics and wearable MedTech |
| Flagler Health | USA | Series B | $50M | Musculoskeletal care technology and AI-enabled MedTech platform |
| Craif | Japan | Series D | $33M | Cancer diagnostics using microRNA biomarkers and AI analysis |
| Renata Medical | USA | Series D | $25M | Commercialization and development of pediatric cardiovascular technologies |
| Qureight | UK | Series B | $20M | AI-enabled imaging platform for lung and heart disease trials |
| Urologic Health | USA/Israel | Seed/equity financing | $11M | Catheter-free urodynamic testing platform |
| Wellinks | USA | Series D | $10M | Cardiopulmonary remote monitoring and heart failure management |
| Vexev | Australia/USA | Venture financing | $6M | Autonomous vascular ultrasound imaging platform for dialysis monitoring |
| Capitan Orthopedics | USA | Seed/equity financing | $4.1M | Orthopedic implant products for shoulder surgery |
| Meduloc | USA | Series B | $4.0M | Flexible nitinol intramedullary fracture fixation platform |
| KOVE Medical | France | Seed/equity financing | €1.7M | Fetal surgery devices and minimally invasive surgical technologies |
Announced M&A
- KKR acquired Integer for $5.7 billion.
- Montagu and Kohlberg acquired Ingenyx for $1.5 billion.
- Teledyne Technologies acquired Varex Imaging for $1.1 billion.
- Astorg acquired Thermo Fisher’s Microbiology Diagnostics Business for $270 million.
- iRhythm acquired VitalConnect for $288 million.
- Globus Medical acquired HiggsBosonHealth; terms were not disclosed.
- H.B. Fuller acquired Advanced Medical Solutions (AMS) for $1.1 billion.
Clinical Trial Starts by Therapeutic Area
Industry-funded interventional trial starts declined from 79 in July to 69 in August 2026, continuing a downward trend from a March and April peak above 100. Cardiovascular clinical trials remained the leading therapeutic area by volume, accounting for 24% of year-to-date trial starts (167), followed by neurology (77), musculoskeletal and ophthalmology (52 each), dermatology and wound care (49) and metabolic and endocrinology (51), oncology (42), ENT (40), gastroenterology (31), pulmonary and critical care (30), diagnostics and monitoring (22), and urology (19).
Regulatory and Market Access Trends
Regulators across major markets staked out new positions on AI oversight in August, while several markets raised entry costs or enforcement scrutiny for MedTech companies. This builds on Avania’s ongoing regulatory strategy and submissions work supporting clients through shifting global requirements.
- The FDA floated a generative AI approach in a discussion paper published August 18. The paper scores device autonomy against severity of harm and proposes voluntary Foundation Model Device Master Files for confidential model information. This is a discussion paper, not guidance, and comments close October 19.
- The FDA finalized Class II status for oncology companion in situ hybridization tests, proposed Class II for cystoscopic systems, and floated Class I for seven accessories, with comments due October 16.
- EU AI Act Article 50 transparency disclosure duties took effect August 2, with fines reaching €15 million or 3% of global turnover.
- New packaging rules under PPWR took effect August 12. There is no blanket exemption for devices or IVDs, though the European Commission’s FAQ points to a warning-first approach.
- The EU MDR revision faces December votes, with Parliament’s health committee voting December 3 and ministers aiming for a Council position in December.
- Devices placed on the market after May 28, including legacy devices, must be registered in EUDAMED by November 28.
- MHRA proposed higher fees on August 17. The annual PMS registration fee would rise from £300 to £511 per GMDN level 2 category, and a Device Regulatory Advice meeting would rise from £987 to £2,245 starting April 2027. Comments close September 25.
- MHRA enforcement notice DSI/2026/007, issued August 10, told users to quarantine six product lines lacking valid UKCA or CE marking. No defect was found in the devices themselves.
- Health Canada now holds Class III and IV applicants accountable for AI-generated summaries in their submissions, effective July 16.
- Class II to IV device trial sponsors are encouraged to register trials within 21 days of first enrollment and post results within 12 months.
- MDEL relief is expected in December, allowing foreign distributors selling only through licensed importers to operate without a licence.
- Four overseas device makers were suspended from import, sale, and use in China between August 3 and 27, with 33 manufacturers on NMPA’s 2026 inspection plan.
- One suspended manufacturer lost its Volume-Based Procurement award and national tender eligibility until February 2028.
- South Korea introduced an AI maker certification process on August 12, allowing certified firms to file lighter dossiers and seek provisional approval backed by real-world data.
- India will accept EU approvals for clinical investigation waivers for novel devices sold for at least two years in the EU, effective August 14.
- Australia’s TGA proposed publishing device review outcomes, even for compliant devices, with comments closing October 2.
CMS Coverage Pathway and Software Payment Changes
CMS advanced two significant proposals in August that reshape how MedTech innovators plan for market access and reimbursement strategy.
- The RAPID pathway, published as a proposed notice on August 11, would issue a proposed National Coverage Determination the same day the FDA authorizes an eligible device, targeting 60 to 90 days to a final coverage decision.
- Entry to RAPID requires Breakthrough Device designation. Presumptive Class II devices must also carry FDA’s Total Product Life Cycle Advisory Program heading for a De Novo pathway, while Class III devices need only a planned PMA. Entry occurs at the IDE pre-submission stage.
- The Transitional Coverage for Emerging Technologies pathway is paused for new candidates, and IVDs are excluded. Devices already in IDE studies are shut out unless CMS adopts a temporary on-ramp it has floated. Comments on this element close October 13.
- Separately, the CY2027 outpatient payment proposal published July 7 names 36 codes as Software as a Medical Service, paid separately under a new payment indicator. CMS would move 21 already-paid codes into New Technology Ambulatory Payment Classifications and describes CY2027 as transitional, holding rates near CY2026 levels.
- A companion physician fee schedule proposal published July 16 would tighten eligibility: removing outsourced staff from Remote Physiological Monitoring and Remote Therapeutic Monitoring eligibility, applying contractor pricing to ten Software as a Medical Service lab analyses, and asking whether 17 codes should be consolidated to four.
RAPID comments close October 13, with payment finals expected in November.
FDA PMA Approvals, August 2026
- RefluxStop Device and RefluxStop Deployment Tool (Implantica CE Reflux, Ltd.): an implantable, medical-grade silicone device designed to treat acid and non-acid GERD.
- BAGUERA C Cervical Disc Prosthesis (Spineart USA, Inc.): a motion-preserving cervical disc designed to treat symptomatic cervical degenerative disc disease between levels C3 and C7.
- Dilight (roflufocon E) Overnight Orthokeratology Contact Lens (Tianjin MasterVision Technology Co., Ltd.): indicated for the reduction of myopic refractive error in non-diseased eyes, for overnight wear, for temporary reduction of myopia up to 4.00 diopters in eyes with astigmatism up to 1.50 diopters.
August’s approvals bring the 2026 year-to-date PMA total to 30, compared with 41 for full-year 2025. Cardiovascular remains the leading panel by approvals, accounting for 20% of 2026 year-to-date PMA approvals, followed by general and plastic surgery and gastroenterology and urology.
FDA De Novo Approvals, August 2026
- Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System (Abbott Diabetes Care): a wearable device that continuously tracks glucose and ketone concentrations using a single sensor.
- ReneuRx (Brixton Biosciences): a nerve-selective biomaterial injected around a target treatment area to interrupt pain signals, with an initial target market of orthopedic pain.
- Auvulux (Matap ii, LLC): lenses designed to filter light and decrease the impact of light sensitivity in people living with episodic migraines.
- Qoramatic Automated Stool Management (CM Technologies, Inc.): a closed-loop stool management kit that does not require balloon inflation to anchor the device.
- Aletta Autonomous Robotic Phlebotomy Device, Gen1 US (Vitestro): a standalone robotic device that draws blood from a patient’s arm without hands-on operator intervention, authorized for use in adults in outpatient settings under the oversight of a supervisor trained in phlebotomy.
FDA Humanitarian Device Exemption, August 2026
OncoSil (OncoSil Medical USA, Inc.) is intended for intratumoral implantation into a solid tumor via injection under endoscopic ultrasound guidance. It is indicated for the treatment of patients with distal cholangiocarcinoma that is both unresectable and non-metastatic, as an adjunct to systemic therapy.
Frequently Asked Questions
It’s Avania’s monthly briefing on MedTech regulatory changes, funding trends, clinical trial activity, and M&A, built for device, diagnostic, and digital health companies tracking the global landscape.
RAPID is a proposed National Coverage Determination pathway that CMS published as a notice in August 2026. If finalized as proposed, it would issue a proposed coverage decision the same day the FDA authorizes an eligible Breakthrough Device, with CMS targeting 60 to 90 days to a final decision. The pathway is not yet final, and comments remain open through October 13, 2026.
The FDA published a discussion paper, not draft guidance, on August 18, 2026 that explores a framework for evaluating generative AI in medical devices. The paper proposes scoring device autonomy against the severity of potential harm and floats a voluntary Foundation Model Device Master File that manufacturers could use to share confidential model information with the agency. Public comments are open through October 19, 2026.
Catch up on the July 2026 MedTech Industry Pulse for last month’s recap.
The MedTech Market Is Consolidating. Regulatory Demands Are Rising.
Your clinical trial has to generate evidence that regulators will accept AND that supports market access reimbursement. Avania’s Clinical Development team doesn’t design in isolation. Regulatory strategy and market access experts are embedded from the start. Your protocol is built to win on both fronts simultaneously. No rework. No delays.
Get Your Copy Now
Ready to Advance
Your MedTech?
Let's Accelerate Your Journey.